MRSA Testing Market

Executive Summary

MRSA Testing Market was valued at US $10.31 billion in 2021 and is projected to grow at 18.55% CAGR over the forecast period to reach US $28.64 billion by 2027. MRSA Testing Market represented US $2.98 billion opportunity over 2019-2021 and estimated to create US $18.32 billion opportunity in 2027 over 2021.

MRSA Testing from Consainsights analyses the MRSA Testing Market in the Life Sciences industry over the forecast period to 2027.

MRSA Testing research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

MRSA Testing segmentation includes Type, Application and Geography.

Based on the Type, the MRSA Testing analysis covers IMMUNODIAGNOSTICS, MOLECULAR DIAGNOSTICS.

In Type segment, IMMUNODIAGNOSTICS segment has highest cagr growth of 16.33%.

Based on the Application, the MRSA Testing analysis covers HOSPITALS, DIAGNOSTIC LABORATORIES, ACADEMIC AND RESEARCH INSTITUTES.

In Application segment, HOSPITALS segment has highest cagr growth of 16.33%.

Based on the region, the MRSA Testing analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include BD MEDICAL, F.HOFFMANN-LA ROCHE, HAIN LIFESCIENCE, BIOMERIEUX, 3M COMPANY, BIO-RAD LABORATORIES, ABACUS DIAGNOSTICA, ALERE INC, PURITAN MEDICAL, DIATHERIX and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, IMMUNODIAGNOSTICS segment has the highest revenue of US $7.76 billion and is expected to grow at CAGR of 16.33% by 2027 IMMUNODIAGNOSTICS segment has highest cagr growth of 16.33%.

IMMUNODIAGNOSTICS

IMMUNODIAGNOSTICS segment was valued at US $5.52 billion in 2019 and is projected to grow at 16.33% CAGR over the forecast period to reach US $21.56 billion by 2027. IMMUNODIAGNOSTICS segment represented US $2.24 billion opportunity over 2019-2021 and estimated to create US $13.79 billion opportunity in 2027 over 2021.

MOLECULAR DIAGNOSTICS

MOLECULAR DIAGNOSTICS segment was valued at US $1.81 billion in 2019 and is projected to grow at 16.33% CAGR over the forecast period to reach US $7.08 billion by 2027. MOLECULAR DIAGNOSTICS segment represented US $0.74 billion opportunity over 2019-2021 and estimated to create US $4.53 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, HOSPITALS segment has the highest revenue of US $4.59 billion and is expected to grow at CAGR of 16.33% by 2027 HOSPITALS segment has highest cagr growth of 16.33%.

HOSPITALS

HOSPITALS segment was valued at US $3.27 billion in 2019 and is projected to grow at 16.33% CAGR over the forecast period to reach US $12.74 billion by 2027. HOSPITALS segment represented US $1.32 billion opportunity over 2019-2021 and estimated to create US $8.15 billion opportunity in 2027 over 2021.

DIAGNOSTIC LABORATORIES

DIAGNOSTIC LABORATORIES segment was valued at US $3.05 billion in 2019 and is projected to grow at 16.33% CAGR over the forecast period to reach US $11.92 billion by 2027. DIAGNOSTIC LABORATORIES segment represented US $1.24 billion opportunity over 2019-2021 and estimated to create US $7.63 billion opportunity in 2027 over 2021.

ACADEMIC AND RESEARCH INSTITUTES

ACADEMIC AND RESEARCH INSTITUTES segment was valued at US $1.02 billion in 2019 and is projected to grow at 16.33% CAGR over the forecast period to reach US $3.97 billion by 2027. ACADEMIC AND RESEARCH INSTITUTES segment represented US $0.41 billion opportunity over 2019-2021 and estimated to create US $2.54 billion opportunity in 2027 over 2021.